|
1
|
Wong MCS, Lao XQ, Ho KF, Goggins WB and
Tse SLA: Incidence and mortality of lung cancer: Global trends and
association with socioeconomic status. Sci Rep. 7:143002017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. In J Cancer. 136:E359–E386. 2015.
|
|
3
|
Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu
S, Li Y, Wang L, Liu Y and Yin P: Cause-specific mortality for 240
causes in China during 1990–2013: A systematic subnational analysis
for the global burden of disease study 2013. Lancet. 387:251–272.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prabhu VV and Devaraj N: Epidermal growth
factor receptor tyrosine kinase: A potential target in treatment of
non-small-cell lung carcinoma. J Environ Pathol Toxicol Oncol.
36:151–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goss G, Tsai CM, Shepherd FA, Bazhenova L,
Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, et al:
Osimertinib for pretreated EGFR Thr790Met-positive advanced
non-small-cell lung cancer (AURA2): A multicentre, open-label,
single-arm, phase 2 study. Lancet Oncol. 17:1643–1652. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghafoor Q, Baijal S, Taniere P, O'Sullivan
B, Evans M and Middleton G: Epidermal growth factor receptor (EGFR)
kinase inhibitors and non-small cell lung cancer (NSCLC)-advances
in molecular diagnostic techniques to facilitate targeted therapy.
Pathol Oncol Res. 24:723–731. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Wang Y, Niu K, Chen X, Xia L, Lu D,
Kong R, Chen Z, Duan Y and Sun J: Clinical benefit from EGFR-TKI
plus ginsenoside Rg3 in patients with advanced non-small cell lung
cancer harboring EGFR active mutation. Oncotarget. 7:70535–70545.
2016.PubMed/NCBI
|
|
13
|
Li ZX, Qu LY, Wen H, Zhong HS, Xu K, Qiu
XS and Wang EH: Mig-6 overcomes gefitinib resistance by inhibiting
EGFR/ERK pathway in non-small cell lung cancer cell lines. Int J
Clin Exp Pathol. 7:7304–7311. 2014.PubMed/NCBI
|
|
14
|
Zheng R, Jiang H, Li J, Liu X and Xu H:
Polyphyllin II restores sensitization of the resistance of PC-9/ZD
cells to gefitinib by a negative regulation of the PI3K/Akt/mTOR
signaling pathway. Curr Cancer Drug Target. 17:376–385. 2017.
View Article : Google Scholar
|
|
15
|
Song S, Du L, Jiang H, Zhu X, Li J and Xu
J: Paris saponin I sensitizes gastric cancer cell lines to
cisplatin via cell cycle arrest and apoptosis. Med Sci Monit.
22:3798–3803. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang H, Zhao PJ, Su D, Feng J and Ma SL:
Paris saponin I induces apoptosis via increasing the Bax/Bcl-2
ratio and caspase-3 expression in gefitinib-resistant non-small
cell lung cancer in vitro and in vivo. Mol Med Rep.
9:2265–2272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun M, Ye Y, Xiao L, Duan X, Zhang Y and
Zhang H: Anticancer effects of ginsenoside Rg3 (Review). Int J Mol
Med. 39:507–518. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang Z, Yang Y, Yang Y, Zhang Y, Yue Z,
Pan Z and Ren X: Ginsenoside Rg3 attenuates cisplatin resistance in
lung cancer by downregulating PD-L1 and resuming immune. Biomed
Pharmacother. 96:378–383. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim YJ, Choi WI, Jeon BN, Choi KC, Kim K,
Kim TJ, Ham J, Jang HJ, Kang KS and Ko H: Stereospecific effects of
ginsenoside 20-Rg3 inhibits TGF-beta1-induced
epithelial-mesenchymal transition and suppresses lung cancer
migration, invasion and anoikis resistance. Toxicology. 322:23–33.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Socinski MA, Evans T, Gettinger S, Hensing
TA, VanDam Sequist L, Ireland B and Stinchcombe TE: Treatment of
stage IV non-small cell lung cancer: Diagnosis and management of
lung cancer, 3rd ed: American college of chest physicians
evidence-based clinical practice guidelines. Chest. 143 Suppl
5:e341S–e368S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baselga J and Arteaga CL: Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bareschino MA, Schettino C, Rossi A,
Maione P, Sacco PC, Zeppa R and Gridelli C: Treatment of advanced
non small cell lung cancer. J Thorac Dis. 3:122–133.
2011.PubMed/NCBI
|
|
25
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL and Yang PC: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu C, Zhou Q and Wu YL: Can EGFR-TKIs be
used in first line treatment for advanced non-small cell lung
cancer based on selection according to clinical factors?-A
literature-based meta-analysis. J Hematol Oncol. 5:622012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirsh V: Next-Generation covalent
irreversible kinase inhibitors in NSCLC: Focus on afatinib.
BioDrugs. 29:167–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tan CS, Gilligan D and Pacey S: Treatment
approaches for EGFR-inhibitor-resistant patients with
non-small-cell lung cancer. Lancet Oncol. 16:e447–e459. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yver A: Osimertinib (AZD9291)-a
science-driven, collaborative approach to rapid drug design and
development. Ann Oncol. 27:1165–1170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Engel J, Lategahn J and Rauh D: Hope and
disappointment: Covalent inhibitors to overcome drug resistance in
non-small cell lung cancer. ACS Med Chem Lett. 7:2–5. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH,
Kim CH and Lee JC: p53 enhances gefitinib-induced growth inhibition
and apoptosis by regulation of Fas in non-small cell lung cancer.
Cancer Res. 67:1163–1169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JW, Jung SY, Kwon YH, Lee JH, Lee YM,
Lee BY and Kwon SM: Ginsenoside Rg3 attenuates tumor angiogenesis
via inhibiting bioactivities of endothelial progenitor cells.
Cancer Biol Ther. 13:504–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Son KJ, Choi KR, Lee SJ and Lee H:
Immunogenic cell death induced by ginsenoside Rg3: Significance in
dendritic cell-based anti-tumor immunotherapy. Immune Netw.
16:75–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun HY, Lee JH, Han YS, Yoon YM, Yun CW,
Kim JH, Song YS and Lee SH: Pivotal roles of ginsenoside Rg3 in
tumor apoptosis through regulation of reactive oxygen species.
Anticancer Res. 36:4647–4654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tian L, Shen D, Li X, Shan X, Wang X, Yan
Q and Liu J: Ginsenoside Rg3 inhibits epithelial-mesenchymal
transition (EMT) and invasion of lung cancer by down-regulating
FUT4. Oncotarget. 7:1619–1632. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang J, Tian L, Khan MN, Zhang L, Chen Q,
Zhao Y, Yan Q, Fu L and Liu J: Ginsenoside Rg3 sensitizes hypoxic
lung cancer cells to cisplatin via blocking of NF-κB mediated
epithelial-mesenchymal transition and stemness. Cancer Lett.
415:73–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Joo EJ, Chun J, Ha YW, Ko HJ, Xu MY and
Kim YS: Novel roles of ginsenoside Rg3 in apoptosis through
downregulation of epidermal growth factor receptor. Chem Biol
Interact. 233:25–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
